🚀Promising Phase II/III trial of albendazole and ivermectin (fixed doses) co-formulation for treatment of soil-transmitted helminthiases. 🔎 Alejandro Krolewiecki and colleagues have reported the results of an adaptive phase 2/3 randomised controlled superiority trial comparing the standard regimen of a single dose of 400 mg albendazole versus two experimental fixed-dose co-formulations (FDCs) of albendazole and ivermectin for the treatment of soil-transmitted helminthiases. ⚖️ Trial was conducted in 15 schools in Kenya, Mozambique, and Ethiopia enrolling 1001 children/adolescents (aged 518 years) with infection. The primary outcome of phase 2 (conducted in Kenya only) was safety during the first 3 hours after the intervention and for 7 days, and the primary outcome of phase 3 was cure rate of Trichuris trichiura. Researchers demonstrated the safety and efficacy above the current standard for the treatment of geohelminths. For Trichuris trichiura, cure rate of the triple dose and the single dose both had higher cure rate (97·2% and 82·9%, respectively) compared with albendazole alone (35·9%). Difference between groups was 47·0 (36·6 to 56·5) percentage points for the single dose and 61·3 (51·9 to 69·8) for the three-day dose. 💡 FDCs may encourage the use of a safe and effective combination treatment instead of monotherapy in soil-transmitted helminth control programmes to enhance preventive chemotherapy against soil-transmitted helminths, including Strongyloides stercoralis, and slow down the emergence of resistance. Questions for wider implementation are affordability, large scale accessibility, and generalizability of the findings. Data has been submitted to the European Medicines Agency for regulatory approval. Here is the paper: https://bit.ly/40EBE4A Here is the comment by Dora Buonfrate: bit.ly/4gYURnj #albendazole #ivermectin #helminths #MundoSano #EDCTP
The Lancet Infectious Diseases’ Post
More Relevant Posts
-
Superbugs could be attributed to over 39 million deaths by 2050 according to a new study by the Global Research on Antimicrobial Resistance (GRAM) Project published in The Lancet. Although deaths related to drug resistance are decreasing among young children due to better vaccination and hygiene, the study forecasts a sharp increase in AMR-related deaths among the elderly. Phages offer a promising alternative or complement to traditional drugs against bacteria. Unlike antibiotics, which target a broad range of pathogenic agents, phages are highly specific, reducing the risk of antimicrobial resistance. This precision makes phages a great asset in fighting resistant infections. The time to take action is now. The research: https://lnkd.in/e8XJcQ7Y #ScienceWorks #AMR #GlobalHealth
-
Helping Patients Navigate Life-Saving Treatments | Patient Advocate| Registered nurse, BLS, IMCI, content creator, certified CPR provider. .
WHY YOU MUST NOT GIVE ZINC TABLET TO A PATIENT USING ANTIMALARIAL MEDICATIONS. I was perplexed when I saw a doctor's note that "withold tab zinc until ACT (arthemeter) tablets is exhausted ". This made me to ask and research why we must follow his order. Antimalarial medications and zinc tablets should not be taken together because zinc can interact with certain antimalarial drugs, reducing their absorption and effectiveness. Here are some reasons why: 1. Reduced absorption: Zinc can bind to antimalarial drugs like chloroquine, mefloquine, and quinine, reducing their absorption into the bloodstream. 2. Decreased efficacy: By reducing the absorption of antimalarial drugs, zinc can decrease their effectiveness in treating malaria. 3. Increased risk of treatment failure: Taking zinc with antimalarial medications can increase the risk of treatment failure, which can lead to more severe malaria symptoms, poorly treated malaria and complications. It's essential to consult with a healthcare professional before taking any medications, including antimalarial drugs and zinc supplements, to ensure safe and effective treatment. #nursefatodu
-
-
Associate Professor in Pharmacology, Faculty of Pharmaceutical Sciences, Assam down town University, Guwahati, Assam/Editor in Springer, Singapore & Bentham Science, UAE
🚨 Antibiotics: Our Lifesavers Under Threat 🚨 Antibiotics have revolutionized medicine, saving millions of lives. But their overuse and misuse have fueled the rise of antibiotic-resistant "superbugs", making infections harder—and sometimes impossible—to treat. 🦠 In 2021, these superbugs caused 1.14 million deaths globally (The Lancet). India is among the worst affected, with 300,000 deaths in 2019, including 60,000 newborns lost each year due to resistant infections. 💡 There’s hope! Promising locally-developed drugs are emerging to combat these superbugs, preserving critical treatments for future generations. 💊 What can you do? ✔️ Use antibiotics only when prescribed. ✔️ Follow the full course of treatment. ✔️ Avoid self-medication or pressuring doctors for antibiotics. Together, let’s fight antimicrobial resistance and protect the power of antibiotics! 🌍✨ #AntibioticAwareness #Superbugs #SaveLives
-
🚨 Breaking News: Shionogi’s Cefiderocol Approved in Australia! 🇦🇺 Shionogi & Co., Ltd. has achieved a significant milestone with the Therapeutic Goods Administration (TGA) granting approval for cefiderocol, a groundbreaking treatment for resistant gram-negative bacterial infections. 💡 Key Highlights: - Expands treatment options for multidrug-resistant infections. - Proven success in global clinical trials, targeting complex urinary tract infections and more. - Collaborations with GARDP and CHAI aim to enhance access in low- and middle-income countries. With antimicrobial resistance (AMR) affecting over a million lives annually, cefiderocol stands as a crucial weapon against this global health crisis. Shionogi’s commitment to public health ensures that this essential medicine reaches those who need it most. 💪 Together, we can combat AMR! 👉 Click the link to learn more about this vital development! 🌍 #AntimicrobialResistance #Cefiderocol #GlobalHealth #Healthcare #Pharma #RegulatoryAgencies #Shionogi #MarketAccess #MarketAccessToday
-
Socioeconomic Inequities Have a Significant Impact on Treatment of Antimicrobial Resistant Infections: Pharmacist-led interventions significantly improve antibiotic prescribing practices, optimize therapy, and improve patient outcomes. #finance #pharmacy #lifesciences
-
Community-wide antibiotic use in rural, low-income Burkina Faso is threefold lower than the average in middle-income countries, but comparable to what we estimated earlier in rural DR Congo (https://lnkd.in/e7dBYSix). Yet the proportion of primary care visits resulting in antibiotic use is comparable to that elsewhere, but use of the clinically most important, so-called Watch antibiotics, is lower than elsewhere. Still, most antibiotic use was in patients with clinical presentations for which generally no antibiotics are needed: malaria, followed by bronchitis, rhinitis or pharyngitis, and gastro-enteritis. Great work by Daniel VALIA and colleagues at Clinical Research Unit of Nanoro (CRUN / URCN)
-
European Medicines Agency Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 November 2024 ~Doxycycline (broad-spectrum antibiotic): currently available evidence doesn't support a link with the risk of suicidality. ~Veoza (fezolinetant) for treatment of vasomotor symptoms associated with menopause: recommended monitoring liver function to minimise the risk of liver injury. https://lnkd.in/eJBFNxFM
-
The document is a draft of standard evaluation protocols for In-Vitro Diagnostics (IVDs) related to arboviruses, developed by the Indian Council of Medical Research (ICMR) and the Central Drugs Standard Control Organization (CDSCO). It is open for public comments until February 15, 2025. Key points include: 1. Purpose: To establish uniform performance evaluation protocols for IVDs used in diagnosing infections such as Chikungunya, Dengue, and Zika. 2. Protocols Covered: 🔴Chikungunya: IgM ELISA, IgM RDT, real-time PCR. 🔴Dengue: NS1 RDT, NS1 ELISA, IgM RDT, IgM ELISA, NS1/IgM combo RDT, real-time PCR. 🔴Zika: real-time PCR. 3. Requirements: Details on the supply of kits, evaluation sites, reference test kits, and laboratory supplies. 4. Procedure: Study designs, preparation of evaluation sites, and protocols for sample preparation, testing, and data handling. 5. Ethical Approvals: Generally exempted but requires self-declaration or ethics committee information. 6. Sample Size and Composition: Guidelines on sample sizes based on sensitivity and specificity claims. 7. Test Reproducibility: Criteria for lot-to-lot and reader-to-reader reproducibility. 8. Acceptance Criteria: Sensitivity and specificity thresholds are set for each test. 9. Submission for Feedback: Stakeholders are invited to provide comments in a specific format by email.
